SharonAI Updates Resale Prospectus with Q2 2026 Financials and Material Weakness Disclosure
SHAZ has more than doubled off its 52-week low of $16.55.
Summary
SharonAI's prospectus supplement incorporates Q2 2026 results showing a $430.4M net loss, a material weakness in financial controls, and $8.8B in total contract value, while updating resale registrations for shares and convertible notes.
Key Events · Financing and Capital Events · SHAZ
-
Q2 2026 Net Loss of $430.4M
Net loss of $430.4 million for Q2 2026, including a $400.4 million non-cash fair value loss on convertible notes driven by share price appreciation, compared to a $2.6 million loss in Q2 2025.
-
Material Weakness in Internal Controls
Management concluded disclosure controls and procedures were not effective as of June 30, 2026, due to a material weakness in accounting for complex financial instruments, continuing from December 31, 2025.
-
Total Contract Value Reaches $8.8B
Total contract value of approximately $8.8 billion as of August 6, 2026, including a $1.32 billion five-year take-or-pay contract with a global AI lab and a $373 million contract with a global AI platform.
-
CFO Transition Announced
Tim Broadfoot will resign as CFO effective August 24, 2026, with Anuj Goel appointed as successor, as disclosed in the Q2 2026 report.
Analysis · SHAZ · Technology
This prospectus supplement incorporates the Q2 2026 10-Q and 10-Q/A, revealing a $430.4 million net loss driven by a $400.4 million non-cash fair value loss on convertible notes as the share price rose. It also discloses a continuing material weakness in internal controls over complex financial instruments. The filing updates the resale registration for over 5.3 million shares and convertible notes, and includes new contract wins totaling $8.8 billion in TCV, including a $1.32 billion AI lab deal. The CFO transition effective August 24, 2026 adds governance uncertainty.
At the time of this filing, SHAZ was trading at $72.15 on NASDAQ in the Technology sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $16.55 to $97.48. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.